β-hydroxybutyrate with short-course radiotherapy, immunotherapy and CAPEOX before surgery for locally advanced rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective phase II trial will enroll adults with histologically confirmed locally advanced rectal adenocarcinoma (inferior margin ≤10 cm from the anal verge) and ECOG performance status 0–1. Participants will receive short-course radiotherapy with concurrent β-hydroxybutyrate supplementation, followed by sequential immunotherapy combined with CAPEOX (capecitabine and oxaliplatin) as neoadjuvant treatment prior to total mesorectal excision (TME). Laboratory monitoring and predefined safety criteria are required, and treatment response and surgical outcomes will be recorded. The study is single-center at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients or their family members agree to participate in the study and sign the informed consent form;
2. Age 18-75 years, male or female;
3. Histologically confirmed Locally Advanced rectal adenocarcinoma;
4. inferior margin ≤ 10 cm from the anal verge;
5. ECOG performance status score is 0-1;
6. Untreated with anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, surgery, etc;
7. There was no operative contraindication;
8. Laboratory tests were required to meet the following requirements: white blood cell (WBC) ≥ 4×109/L; Absolute neutrophil count (ANC) ≥ 1.5×109/L; Platelet count ≥ 100×109/L; Hemoglobin ≥90 g/L; Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN); Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Serum creatinine ≤1.5 times the upper limit of normal value or creatinine clearance rate ≥50 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
9. Urinary protein \< 2+ or 24-hour urinary protein excretion \< 1 g at baseline.

Exclusion Criteria:

1. Patients with non-pMMR LARC；
2. Subjects who have previously received any form of immunotherapy, including but not limited to immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or any other treatment targeting tumor immunomodulatory mechanisms;
3. Presence of any concurrent disease, condition (including laboratory abnormality), history of substance abuse, or current evidence thereof, which, in the judgment of the Investigator, may compromise subject safety, interfere with the process of obtaining informed consent, affect subject compliance, or confound the safety assessment of the investigational product(s).

Where it's running

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Zhenyu Lin — Huazhong University of Science and Technology Tongji Medical College Union Hospital
• Study coordinator: Zhenyu Lin, MD
• Email: whxhlzy@hust.edu.cn
• Phone: 027-83262683

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-course versus short-course radiotherapy before immunotherapy and total neoadjuvant therapy for locally advanced rectal cancer

  This trial tests whether adding immunotherapy to total neoadjuvant therapy and using short-course versus long-course radiotherapy improves outcomes for adults with locally advanced rectal cancer.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07113275

• Adebelizumab with chemotherapy given with radiotherapy at the same time versus after radiotherapy for extensive-stage small cell lung cancer

  This study tests whether adding adebelizumab to chemo and radiotherapy works better when given at the same time as radiotherapy compared to after radiotherapy in adults with extensive-stage SCLC.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06768307

• Comparing total neoadjuvant therapy with surgery for rectal cancer treatment

  This study is testing if rectal cancer patients who respond well to a new treatment can skip surgery and just be monitored to see how they do compared to those who have surgery right away.

  Recruiting Phase 2/3 National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos · Vilnius · NCT06758830

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

• Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer

  This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07646639

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.